Short answer
Hologic (HOLX) filed its Q4 2025 10-Q quarterly report on Jan 29, 2026 for the quarter ended Dec 27, 2025. Quarterly revenue was $1.0B (up 2.5% year over year) with net income of $179M.
Q4 2025 key financials · XBRL
- Revenue
- $1.0B
- +2.5% YoY
- Net income
- $179M
- −10.9% YoY
- Operating margin
- 22.6%
- Gross margin
- 56.0%
- EPS (diluted)
- $0.79
- −9.2% YoY
Source: XBRL data from the Hologic (HOLX) Q4 2025 10-Q on SEC EDGAR. USD.
Hologic Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.05B total ($831.4M product + $216.4M service), product revenues up 1.7% YoY from $817.9M, driven by GYN Surgical (+8.0%) and Skeletal Health (+124.3%), partially offset by declines in Diagnostics (-0.8%) and Breast Health (-2.2%)
- Operating margin by segment: Diagnostics 33.9% vs 33.0% YoY (+0.9pp); Breast Health 27.3% vs 24.3% YoY (+3.0pp); GYN Surgical 22.4% vs 35.2% YoY (-12.8pp); Skeletal Health 10.5% vs -19.6% YoY (+30.1pp)
- Best performing segment: Skeletal Health revenue +69.0% to $26.7M with improved operating income $2.8M vs loss $3.1M prior year; Worst performing: GYN Surgical lowest margin and operating income fell 30.9% despite 8.7% revenue increase
- Cash and equivalents increased $208.5M to $2.17B; Operating cash flow $229.9M driven by net income $179.1M; Investing cash use $12.1M primarily capital expenditures and investments; Financing cash use $10.7M due to employee tax payments and equity plan proceeds
- Management highlights ongoing Brevera 9 Gauge Needle stop-ship and recall weighing on Breast Health product revenues; merger agreement with Blackstone and TPG expected closing H1 2026; expects sufficient liquidity over next 12 months; cautious on COVID testing volume decline and macroeconomic risks
Risk Factors
- Ongoing COVID-19 pandemic impact on supply chain and demand remains a key carried-forward risk
- Dependency on third-party suppliers could disrupt manufacturing and affect revenue continuity
- Regulatory scrutiny on diagnostic products could delay approvals or increase compliance costs
- Competition from new entrants and technologies threatens market share and pricing power
- Debt maturity schedule requires $600 million repayment by 2026, posing liquidity pressure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Hologic quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.